UNSPSC 51293202: Phenelzine

This classification denotes a monoamine oxidase inhibitor and antidepressant agent with the molecular formula C8H12N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O408N561GF, chemically known as hydrazine, phenethyl-, monohydrochloride but generally known as phenelzine, which bears US NIH Compound Identifier 3675. European Medicines Agency schedules Phenelzine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09757MIG. The term PHENELZINE is an International Non-Proprietary Name.

UNSPSC 51293202 Phenelzine is a Commodity code that in practice covers pharmaceutical procurement by state and local health agencies, though the recent activity recorded against it does not reflect the specific active pharmaceutical ingredient. Seminole County, Florida's IFB60459723LAS solicitation, posted June 30, 2026 with a response deadline of July 26, 2023, sought 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives—a mismatch that reflects how state and local procurement offices sometimes tag health-sector pharmaceutical and medical-supply acquisitions broadly rather than to granular ingredient-level codes. The work itself involves competitive bidding for medical countermeasures and harm-reduction supplies, with vendors responsible for quarterly deliveries, E-Verify compliance, drug-free workplace certification, standard commercial insurance, and FEMA-related federal compliance obligations when applicable.

The geographic data and issuing-body pattern rest on a single recent opportunity. Seminole County, a Florida county government, conducted the sole documented recent solicitation under this code. The procurement was structured as a fixed-fee arrangement with no explicit set-aside designations, a two-year initial term with one-year renewal option, and a three-month probationary termination window. Given the sparse recent-opportunity record, this code shows limited activity in state and local procurement systems and may signal either low demand for competitive bidding on this specific pharmaceutical class or mislabeling of health-sector supplies under higher-level family or segment codes.